Composition containing functional medicinal bean powder biotransformed using Bacillus enzyme group as an active ingredient and its use

A bioconverted medicinal bean powder using Bacillus polyfermenticus KMU01 enzymes addresses the need for natural exercise aids by improving exercise performance and behavioral disorders through antioxidant activity and symptom reduction.

JP7577845B2Active Publication Date: 2024-11-05KOOKMINBIO CORP
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2023518313
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2021-09-17
Filing Date
2021-09-23
Publication Date
2024-11-05
Estimated Expiration
2041-09-23

AI Technical Summary

Technical Problem

Existing exercise performance-enhancing aids, such as caffeine and anabolic steroids, have side effects, and there is a need for natural supplements that can improve exercise performance and address behavioral disorders without adverse effects.

Method used

A bioconverted medicinal bean powder produced using a Bacillus polyfermenticus KMU01 strain is processed with enzymes to form low-molecular functional amino acids and peptides, which are used to create a composition for improving exercise performance and behavioral disorders.

Benefits of technology

The bioconverted powder exhibits antioxidant activity and improves behavioral disorders, including conditions like Parkinson's disease, by enhancing motor performance and reducing symptoms through oral or parenteral administration.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007577845000004
    Figure 0007577845000004
  • Figure 0007577845000005
    Figure 0007577845000005
  • Figure 0007577845000006
    Figure 0007577845000006
Patent Text Reader

Abstract

The present invention relates to a composition containing medicinal bean biotransformation powder in which various physiologically active functions have been improved by treating whole soybean milk with an enzyme solution derived from a Bacillus polyfermenticus strain. It has been confirmed that low molecular weight functional amino acids and peptides are formed by treating whole soybean milk with a fermentation solution containing a mixture of various degradative enzymes and peptide synthesizing enzymes derived from a Bacillus polyfermenticus strain, and that the medicinal bean biotransformation powder exhibits functional effects such as antioxidant activity and the improvement of behavioral disorders. As a result, a composition for improving behavioral disorders containing medicinal bean biotransformation powder as an active ingredient is provided.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a composition containing medicinal bean biotransformation powder as an active ingredient and its use, and more particularly to a composition containing medicinal bean biotransformation powder having various improved physiologically active functions by treating whole soybean milk with an enzyme solution derived from a Bacillus polyfermenticus strain. [Background technology]

[0002] Motor performance is the ability to exercise using muscle strength, and if motor performance declines or becomes unbalanced, it leads to abnormal movement and walking, impairing normal movement and causing poor posture. In addition, a decline in motor performance leads to insufficient exercise, which can lead to problems such as reduced physical strength, obesity, hyperlipidemia, and high blood pressure. Therefore, in order to live a normal and healthy life, it is necessary to improve motor performance.

[0003] Methods for improving athletic performance include regular exercise, dietary therapy, and athletic performance enhancing supplements. Research into functional supplements for improving athletic performance is being actively conducted in both the East and the West. However, most of the athletic performance enhancing supplements used in the West, such as caffeine and anabolic steroids, have side effects. As a result, research has been actively conducted recently to develop functional supplements using natural products with guaranteed safety, but the situation is still insufficient, so research is needed on supplements that effectively enhance athletic performance without side effects.

[0004] Beans are an ideal food with excellent nutritional value, containing healthy protein and fat as well as various functional ingredients, and are therefore very important and essential in the diet. As new physiological functions, such as anti-cancer properties and immune-boosting properties, have been discovered recently, the nutritional value of beans as a functional food is increasing day by day.

[0005] Soy milk, one of the representative processed foods made from soybeans, is a representative soybean processed product that has increased the protein utilization rate of soybeans. It is rich in soybean protein, essential amino acids, and essential fatty acids, and contains a large amount of minerals such as iron, phosphorus, and potassium, and functional ingredients such as isoflavones, saponins, and phytic acid, making it known as a functional nutritional drink. In addition, research is being conducted to improve functionality by treating soybean milk with proteolytic enzymes to break down soybean protein and promote digestion and absorption, as well as producing peptides with physiological activities such as blood pressure enhancement, calcium absorption promotion, anti-allergy, and serum cholesterol lowering effects. However, the effectiveness of soy milk in improving athletic performance is still unknown. [Prior art documents] [Patent documents]

[0006] [Patent Document 1] Republic of Korea Patent Publication No. 10-2011-0027247 (published on March 16, 2011) Summary of the Invention [Problem to be solved by the invention]

[0007] In order to solve the above problems, the present invention provides a medicinal bean biotransformation powder with improved functionality and a manufacturing method thereof. It has been confirmed that low molecular weight functional amino acids and peptides are formed by treating whole soybean milk with a fermentation liquid containing a mixture of various degradative enzymes and peptide synthesizing enzymes derived from a Bacillus polyfermenticus strain, and that medicinal bean biotransformation powder has functional effects such as antioxidant activity and improvement of behavioral disorders. Based on this, a composition for improving behavioral disorders containing medicinal bean biotransformation powder as an active ingredient is provided. [Means for solving the problem]

[0008] The present invention provides a composition for biotransformation comprising a Bacillus polyfermenticus KMU01 (Accession Number: KCTC 11751BP) strain, a culture medium thereof, a fermentation product thereof, or a mixture thereof.

[0009] The present invention also provides a method for producing a medicinal soybean biotransformation powder, comprising treating whole soybean milk with a Bacillus polyfermenticus KMU01 (Accession Number: KCTC 11751BP) strain, a culture solution thereof, a fermentation product thereof, or a mixture thereof.

[0010] The present invention also provides a pharmaceutical composition for preventing or treating behavioral disorders, comprising as an active ingredient whole soybean milk fermented using Bacillus polyfermenticus KMU01 (Accession Number: KCTC 11751BP) strain, its culture solution, its fermentation product, or a mixture thereof.

[0011] The present invention also provides a health functional food composition for preventing or improving behavioral disorders, which contains as an active ingredient whole soymilk fermented using Bacillus polyfermenticus KMU01 (accession number: KCTC 11751BP) strain, its culture solution, its fermentation product, or a mixture thereof. Effect of the Invention

[0012] According to the present invention, it has been confirmed that low molecular weight functional amino acids and peptides are formed by treating whole soybean milk with a fermentation liquid containing a mixture of various degradative enzymes and peptide synthesizing enzymes derived from a Bacillus polyfermenticus strain, and that medicinal bean biotransformation powder has functional effects such as antioxidant activity and improvement of behavioral disorders, thereby providing medicinal bean biotransformation powder and a manufacturing method thereof. [Brief description of the drawings]

[0013] [Figure 1] 1 shows a gene map of the Bacillus polyfermenticus KMU01 strain and a diagram showing genes of enzyme groups. [Diagram 2] The results show the bean protein breakdown profile and the degree of bean peptide production in whole soy milk and medicinal soybean biotransformation powder. [Diagram 3] The antioxidant activity of whole soybean milk and medicinal bean biotransformation powder was evaluated. [Figure 4] The results show that whole soy milk and medicinal soybean biotransformation powder were evaluated for their effectiveness in improving behavioral disorders. [Diagram 5] The results show that whole soy milk and medicinal soybean biotransformation powder were evaluated for their effectiveness in improving behavioral disorders under oxidative stress. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0014] The terms used in this specification are currently common terms that are widely used as much as possible while taking into consideration the functions of the present invention, but these may change depending on the intentions of those skilled in the art, precedents, the emergence of new technologies, etc. In addition, in certain cases, the applicant may arbitrarily select terms, and in such cases, the meanings of the terms are described in detail in the description of the relevant invention. Therefore, the terms used in this specification must be defined based on the meanings of the terms and the overall content of the present invention, rather than simply the names of the terms.

[0015] Unless otherwise defined, all terms used herein, including technical and scientific terms, have the same meaning as commonly understood by those skilled in the art. Terms as defined in commonly used dictionaries should be interpreted to have a meaning consistent with the contextual meaning of the relevant art, and should not be interpreted as idealized or overly formal unless expressly defined herein.

[0016] Numeric ranges are inclusive of the numerical values ​​defined in the range. Every maximum numerical limitation given throughout this specification includes every lower numerical limitation, as if that lower numerical limitation is expressly written. Every minimum numerical limitation given throughout this specification includes every higher numerical limitation, as if that higher numerical limitation is expressly written. Every numerical limitation given throughout this specification includes every greater numerical range within that broader numerical range, as if that narrower numerical limitation is expressly written.

[0017] The present invention will now be described in more detail.

[0018] Taking these points into consideration, the present inventors have made extensive efforts to develop a functional composition containing medicinal bean bioconversion powder having excellent behavioral disorder improving effects, and as a result, have confirmed that a composition containing medicinal bean bioconversion powder obtained by hydrolyzing whole soybean milk using an enzyme group containing a mixture of various proteases and peptide synthetases secreted and produced by GRAS fermented food microorganisms isolated from fermented foods has excellent effects of improving behavioral disorders, thereby completing the present invention.

[0019] The present invention provides a composition for biotransformation comprising a Bacillus polyfermenticus KMU01 (Accession Number: KCTC 11751BP) strain, a culture medium thereof, a fermentation product thereof, or a mixture thereof.

[0020] The bioconversion is a technology to convert existing materials (substrates) using biological reactions of microorganisms or enzymes produced by microorganisms. Specifically, the bioconversion means converting beans or medicinal beans (substrates) using an enzyme group, which is a culture supernatant containing various enzymes produced by the Bacillus polyfermenticus KMU01 (Accession Number: KCTC 11751BP) strain, and the product made through the bioconversion is called medicinal bean bioconversion powder.

[0021] The Bacillus polyfermenticus KMU01 (Accession Number: KCTC 11751BP) strain was deposited at the Korea Comprehensive Biotechnology Center (KCTC) on August 25, 2010 under the name of Bacillus amyloliquefaciens Kimchi. However, since it was later determined that the species name of the strain is Bacillus polyfermenticus, the species name was changed to Bacillus polyfermenticus KMU01 on June 27, 2018.

[0022] The culture medium is an artificial medium in which the Bacillus polyfermenticus KMU01 (Accession Number: KCTC 11751BP) strain is cultured, and the fermented product is a natural medium produced using the Bacillus polyfermenticus KMU01 (Accession Number: KCTC 11751BP) strain.

[0023] The artificial medium is a commercially produced synthetic medium capable of culturing Bacillus polyfermenticus or bacteria, such as, but not limited to, TBS (Tryptic Soy Broth), TSB (Tryptic Soy Broth), NB (Nutrient Broth), and LB (Luria-Bertani broth).

[0024] The natural medium refers to a natural product produced by bacteria, and is, for example, a medium using natural products such as potato, tomato, and milk, but is not limited thereto.

[0025] The culture medium and the fermented product can exhibit protease, GGT (Gamma-glutamyltransferase), and Nattokinase activities.

[0026] The protease is a proteolytic enzyme that hydrolyzes peptide bonds between amino acids that form proteins. Some proteolytic enzymes are exopeptidases that cleave the amino terminus or carboxyl terminus of proteins, while others are endopeptidases (e.g., trypsin, chemotrypsin, pepsin, papain, elastase) that cleave the middle of proteins. The GGT (γ-glutamyl transferase) is an enzyme that transfers the glutamyl group of γ-glutamyl compounds to an appropriate acceptor (amine), and is a type of transacylase. The nattokinase is a thrombolytic enzyme that is produced by Bacillus natto as it ingests and grows the nutrients in beans during fermentation of beans, and contains vitamin B group and a large amount of antioxidant enzymes.

[0027] The present invention also provides a method for preparing a medicinal soybean biotransformation powder, comprising treating whole soybean milk with a Bacillus polyfermenticus KMU01 (Accession Number: KCTC 11751BP) strain, a culture solution thereof, a fermentation product thereof, or a mixture thereof.

[0028] The medicinal bean biotransformation powder refers to a powdered product produced by reacting medicinal beans, which are the fruit of a perennial vine, with microorganisms or enzymes produced by microorganisms to cut or decompose carbohydrates and proteins contained in medicinal beans. Specifically, the medicinal bean biotransformation powder refers to a powdered product produced by converting medicinal beans using an enzyme group, which is a culture supernatant containing various enzymes produced by Bacillus polyfermenticus KMU01 (Accession No.: KCTC 11751BP) strain.

[0029] The medicinal beans refer to beans and plant fruits such as soybeans, white beans, black beans, peas, and the like, but are not limited to the types of the beans and plant fruits.

[0030] The Bacillus polyfermenticus KMU01 (Accession Number: KCTC 11751BP) strain, its culture solution, its fermentation product, or a mixture thereof is treated with whole soy milk at a concentration of 3 to 7% (v / v), preferably at a concentration of 5% (v / v).

[0031] The Bacillus polyfermenticus KMU01 (Accession Number: KCTC 11751BP) strain, its culture solution, its fermentation product, or a mixture thereof can be treated at 35 to 40°C for 3 to 5 hours, preferably at 37°C for 4 hours.

[0032] The medicinal bean biotransformation powder can exhibit antioxidant activity.

[0033] The present invention also provides a pharmaceutical composition for preventing or treating behavioral disorders, comprising as an active ingredient whole soybean milk fermented using Bacillus polyfermenticus KMU01 (Accession Number: KCTC 11751BP) strain, its culture solution, its fermentation product, or a mixture thereof.

[0034] The behavioral disorder is a type of disease such as decreased mobility and reduced sleep time caused by excessive and insufficient dopamine depletion, and includes, for example, movement disorders, cognitive impairment, Parkinson's disease, eating disorders, attention deficit disorders, sleep disorders, etc.

[0035] The pharmaceutical composition of the present invention can be prepared in a unit dose form or can be placed in a multi-capacity container by formulating it with a pharma- ceutically acceptable carrier by a method that can be easily carried out by a person skilled in the art.

[0036] The pharma- ceutically acceptable carriers are those commonly used in formulations, and include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, starch, gum acacia, calcium phosphate, alginic acid, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, and mineral oil, etc. The pharmaceutical composition of the present invention may further include, in addition to the above ingredients, lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspending agents, preservatives, etc.

[0037] In the present invention, the content of the additives contained in the pharmaceutical composition is not particularly limited, and is appropriately adjusted within the range of the additives used in conventional pharmaceutical preparations.

[0038] The pharmaceutical composition is formulated into one or more external preparations selected from the group consisting of an injectable dosage form such as an aqueous solution, a suspension, or an emulsion, a pill, a capsule, a granule, a tablet, a cream, a gel, a patch, a spray, an ointment, a plaster, a lotion, a liniment, a paste, and a cataplasm.

[0039] The pharmaceutical composition of the present invention may contain additional pharma- ceutically acceptable carriers and diluents for formulation. The pharma-ceutically acceptable carriers and diluents include, but are not limited to, excipients such as starch, sugar, and mannitol, fillers and extenders such as calcium phosphate, cellulose derivatives such as carboxymethylcellulose and hydroxypropylcellulose, binders such as gelatin, alginates, and polyvinylpyrrolidone, lubricants such as talc, calcium stearate, hydrogenated castor oil, and polyethylene glycol, disintegrants such as povidone and crospovidone, and surfactants such as polysorbate, cetyl alcohol, and glycerol. The pharma-ceutically acceptable carriers and diluents are biologically and physiologically compatible with the subject. Examples of diluents include, but are not limited to, saline, aqueous buffers, solvents, and / or dispersion media.

[0040] The pharmaceutical composition of the present invention can be administered orally or parenterally (e.g., intravenously, subcutaneously, intraperitoneally or topically) depending on the intended method. For oral administration, it is formulated as tablets, troches, lozenges, aqueous suspensions, oily suspensions, pharmaceutical powders, granules, emulsions, hard capsules, soft capsules, syrups or elixirs. For parenteral administration, it is formulated as injections, suppositories, powders for respiratory inhalation, aerosols for spraying, ointments, powders for application, oils, creams and the like.

[0041] The dosage of the pharmaceutical composition of the present invention may vary depending on the patient's condition and body weight, age, sex, health condition, dietary specificity, properties of the formulation, severity of disease, administration time, administration method, administration period or interval, excretion rate, and drug form, and may be appropriately selected by those skilled in the art. For example, the dosage ranges from about 0.1 to 10,000 mg / kg, but is not limited thereto, and may be administered once or several times a day.

[0042] The pharmaceutical composition may be administered orally or parenterally (e.g., intravenously, subcutaneously, intraperitoneally or topically) depending on the intended method. The pharmacologic effective amount and effective dosage of the pharmaceutical composition of the present invention vary depending on the formulation method, administration mode, administration time and / or administration route of the pharmaceutical composition, and those skilled in the art can easily determine or prescribe the dosage effective for the intended treatment. The pharmaceutical composition of the present invention may be administered once a day or in several divided doses.

[0043] The present invention also provides a health functional food composition for preventing or improving behavioral disorders, which contains as an active ingredient whole soymilk fermented using Bacillus polyfermenticus KMU01 (accession number: KCTC 11751BP) strain, its culture solution, its fermentation product, or a mixture thereof.

[0044] The present invention is generally used as a food product.

[0045] The food composition of the present invention is used as a functional health food. The term "functional health food" refers to a food manufactured and processed using raw materials or ingredients that have functional properties useful to the human body according to the Act on Functional Health Foods, and "functional" refers to the intake of the food for the purpose of regulating nutrients for the structure and function of the human body or obtaining beneficial effects for health purposes such as physiological effects.

[0046] The food composition of the present invention contains a common food additive, and the suitability of the said "food additive" is determined in accordance with the specifications and standards for the said item in accordance with the general provisions and general test methods of the Food Additives Code approved by the Ministry of Food and Drug Safety, unless otherwise specified.

[0047] Examples of items listed in the "Food Additives Code" include chemically synthesized substances such as ketones, glycine, potassium citrate, nicotinic acid, and cinnamic acid; natural additives such as indigo blue dye, licorice extract, crystalline cellulose, sorghum color, and guar gum; and mixed preparations such as sodium L-glutamate preparations, alkaline agents added to noodles, preservative preparations, and tar color preparations.

[0048] The food composition of the present invention can be manufactured and processed into the form of tablets, capsules, powder, granules, liquid, pills, etc.

[0049] For example, among the health functional foods in capsule form, hard capsules can be prepared by mixing the composition according to the present invention with additives such as excipients and filling them into a normal hard capsule, and soft capsules can be prepared by mixing the composition according to the present invention with additives such as excipients and filling them into a capsule base such as gelatin. The soft capsules can contain plasticizers such as glycerin or sorbitol, colorants, preservatives, etc., as necessary.

[0050] The definitions of the terms for the excipient, binder, disintegrant, lubricant, flavoring agent, flavoring agent, etc. are those described in documents known to those skilled in the art, and include those having the same or similar functions, etc. The types of the food are not particularly limited, and include any health functional food in the usual sense.

[0051] In the present invention, the term "prevention" refers to any action of administering a composition according to the present invention to inhibit or delay the onset of a disease. In the present invention, the term "treatment" refers to any action of administering a composition according to the present invention to improve or favorably alter the symptoms of a disease. In the present invention, "amelioration" refers to any action of administering or ingesting a composition according to the present invention to an individual to improve the adverse state of a disease.

[0052] The present invention will be described in detail below with reference to examples to aid in understanding the present invention. However, the following examples are merely illustrative of the contents of the present invention, and the scope of the present invention is not limited to the following examples. The examples of the present invention are provided to more completely explain the present invention to those skilled in the art.

[0053] Example 1. Evaluation of various enzyme activities derived from fermented food microorganisms

[0054] To produce functional medicinal bean biotransformation powder, various enzyme activities of the fermentation strain Bacillus polyfermenticus KMU01 (accession number: KCTC 11751BP) were evaluated.

[0055] First, the activities of protease, GGT (γ-glutamyltransferase), and nattokinase were evaluated. The fermentation strain was inoculated into 50 mL of TSB medium and cultured at 37°C for 24 hours, and the culture supernatant was collected and centrifuged at 8,000 rpm for 20 minutes. The centrifuged culture supernatant was used to evaluate the enzyme activities.

[0056] The activity of the protease was evaluated by placing 0.1 mL of 0.5% azocasein solution as a substrate and 0.1 mL of coenzyme solution in an Eppendorf tube, reacting for 1 hour at 37°C in a thermostatic water bath, and then adding 0.4 mL of 10% trichloroacetic acid solution to stop the reaction. The reaction solution was centrifuged at 13,000 rpm for 5 minutes to collect the supernatant, and 0.6 mL of the supernatant was neutralized by adding 0.6 mL of 0.525N NaOH solution, measuring the absorbance at 420 nm, and the amount of enzyme that liberates 1 ug of tyrosine per minute under these reaction conditions was defined as 1 unit.

[0057] GGT (γ-glutamyltransferase) activity was evaluated by mixing 0.01 mL of coenzyme solution with 0.09 mL of 50 mM phosphate buffer (pH 7.0) containing 0.1 mM rL-glutamyl-p-nitroaniline (p-NA-Glu, Sigma-Aldrich) and reacting at 40°C for 30 minutes, and then adding 0.01 mL of 3.5 N acetic acid to stop the reaction. The amount of liberated p-nitroaniline was measured at 410 nm. Enzyme activity was calculated by plotting a standard curve using p-nitroaniline as the standard solution. GGT enzyme activity was evaluated by calculating 1 unit of GGT enzyme activity as the amount of enzyme that liberates 1 mole of p-nitroaniline from p-NA-Glu per minute.

[0058] The activity of nattokinase was evaluated by mixing 350μl of 50mM borate buffer (pH8.5), 100ul of 1% fibrinogen solution, and 25ul of 10unint thrombin solution, reacting at 37℃ for 10 minutes, adding 25ul of coenzyme solution, and reacting at 37℃ for 1 hour. The reaction was stopped by adding 500ul of 0.2M TCA solution to the reaction solution, and then allowed to stand at 37℃ for 10 minutes. The reaction solution was centrifuged at 8,000rpm for 20 minutes to collect the supernatant, and the absorbance of the collected supernatant was measured at 275nm, and the enzyme activity was calculated according to the following formula to evaluate the thrombolytic enzyme activity.

[0059] Thrombolytic activity (FU / ml)=A1-A0 / 0.01X1 / 60X1 / 0.025XD

[0060] A1: Absorbance value of the sample

[0061] A0: Absorbance value of blank test sample prepared without adding coenzyme solution (blank)

[0062] 0.01: The enzyme activity that increases absorbance by 0.01 in 1 minute

[0063] 60: Enzyme reaction time (min)

[0064] 0.025: amount of enzyme used

[0065] D: Dilution factor of the sample

[0066] As shown in Table 1 below, protease activity was expressed at 78 U / ml, GGT activity was expressed at 3500 mU / ml, and nattokinase activity, which shows thrombus decomposition activity, was expressed at 24 U / ml.

[0067] [Table 1]

[0068] In addition, the dielectric constant of the Bacillus polyfermenticus KMU01 (Accession Number: KCTC 11751BP) strain was analyzed using PacBio_20K sequencer and SMRT 2.3.0 (HGAP2) assembler to confirm the genes of various functional enzymes. As a result, as shown in Figure 1, it was confirmed that the Bacillus polyfermenticus KMU01 (Accession Number: KCTC 11751BP) strain possesses 61 peptidase genes, 23 protease genes, 8 glucosidase genes, 6 lipase genes, 2 GGT (γ-glutamyl transferase) genes, 2 cellulase genes, amylase gene, and nattokinase gene.

[0069] Example 2. Preparation of functional biotransformation powder using fermentation strains

[0070] The enzyme solution for biotransformation of whole soybean milk was prepared by culturing Bacillus polyfermenticus KMU01 (Accession Number: KCTC 11751BP) in TSB medium at 37℃ for 24 hours, and the supernatant was used. To produce whole soybean milk, soybean kernels from Iksan, South Korea were washed, soaked in water for 14 hours, dehydrated, and ground using a grinder while removing water. The ground sample was boiled at 100℃ for 30 minutes to obtain whole soybean milk. The whole soybean milk obtained was treated with the enzyme solution at a ratio of 5% (v / v), reacted at 37℃ for 4 hours to perform biotransformation, and then freeze-dried to produce soybean biotransformation powder.

[0071] [Table 2] Example 3. Evaluation of the degree of hydrolysis of medicinal bean biotransformation powder

[0072] The degree of hydrolysis of protein in the medicinal bean biotransformation powder prepared in Example 2 was evaluated. 2 mL of hydrolysate from each sample was taken and placed in a test tube containing 2 mL of 20% (w / v) trichloroacetic acid (TCA), mixed, and centrifuged (3,000Xg, 10 min). A certain amount of the supernatant was taken and the protein content was measured to calculate the degree of hydrolysis. As a result, the degree of hydrolysis of the medicinal bean biotransformation powder was 53.8%.

[0073] In addition, 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was performed to confirm the difference in molecular weight of soybean proteins. As a result, as shown in Figure 2, the amount of soybean peptides of 10,000 Da or less increased 1.23 times in the soybean biotransformation powder (soybean enzyme-treated soybean milk) compared to the control group (soybean whole soybean milk).

[0074] Example 4. Amino acid composition analysis of medicinal bean biotransformation powder

[0075] The functional amino acids in the medicinal soybean biotransformation powder were analyzed using an automatic amino acid analyzer (Biochrom 30+).As shown in Table 3 below, the content of functional amino acids such as branched chain amino acids (BCAAs) necessary for muscle growth and aromatic amino acids, which are precursor amino acids for neurotransmitters, increased.

[0076] [Table 3]

[0077] Example 5. Evaluation of antioxidant activity of medicinal bean biotransformation powder

[0078] To evaluate the antioxidant activity of the medicinal soybean biotransformation powder, the DPPH radical scavenging activity was analyzed. The DPPH radical scavenging ability was measured by reacting 1.1-diphenyl-2-picryl hydrazyl (DPPH), a stable free radical, with a certain sample solution to measure the degree of DPPH radical reduction using a spectrophotometer. 50ul of sample was mixed with 50ul of 0.1mM DPPH solution, and left in a dark room at room temperature for 30 minutes. The absorbance was measured at 517nm and the degree of radical reduction was calculated compared to the control. Blank absorbance was measured by mixing 50ul of water with 50ul of 0.1mM DPPH solution, and control absorbance for each sample was measured by mixing 50ul of sample with 95% ethanol. Ascorbic acid was used as a positive control sample. As shown in Figure 3, the medicinal soybean biotransformation powder showed 74% higher DPPH radical scavenging activity than the control group (medicinal soybean whole milk).

[0079] Example 6. Evaluation of the effect of medicinal bean bioconversion powder in improving behavioral disorders

[0080] To confirm whether the medicinal soybean bioconversion powder has functional effects such as improving behavioral disorders, a control group (medicinal soybean whole soy milk) and medicinal soybean bioconversion powder (enzyme-treated whole soy milk) were orally administered to fruit flies for five weeks, and the behavioral changes between the feeding and non-feeding groups were evaluated using a climbing assay.

[0081] Drosophila melanogaster has a behavior called negative geotaxis, which has led to its use in many behavioral studies. Negative geotaxis is the behavior of the fruit fly climbing up against gravity after a glass tube or test tube containing the fruit fly is impacted once to drop it to the bottom, and is often used in climbing assays. Parkinson's model fruit fly has a negative geotaxis behavior, but due to the deletion of the dj-1 gene, it shows a lower tendency for negative geotaxis compared to normal individuals. The deletion of the dj-1 gene accelerates the rate of dopamine elimination, resulting in symptoms of Parkinson's disease such as reduced mobility and reduced sleep time.

[0082] The Drosophila used was wild-type Drosophila melanogaster. 1118 and DJ-1B, a Parkinson's model fruit fly ex54 The behavioral disorder improving effect of the medicinal bean biotransformation powder was evaluated using the above. The Parkinson's model Drosophila is a model in which the dj-1 gene is deleted, and the deletion of the dj-1 gene accelerates the rate of dopamine elimination, resulting in phenomena such as reduced mobility and reduced sleep time, which are symptoms of Parkinson's disease. All Drosophila were cultured at a temperature of 25°C and a humidity of 60% with a day / night interval of 12 hours.

[0083] First, to confirm the effect of feeding the medicinal bean biotransformation powder on improving behavioral disorders using the model animal Drosophila, a climbing assay was performed in which the test tube containing the Drosophila was impacted to drop the Drosophila to the bottom, and then the behavior of the Drosophila climbing up against gravity was analyzed.

[0084] Whole soy milk and medicinal soybean biotransformation powder were orally administered to fruit flies for 5 weeks, and a climbing assay, which is a behavioral analysis of fruit flies, was performed in 18cm-long vials. After adapting to the environment at room temperature for 10 minutes, the experiment was performed based on the point at which the fruit flies were completely seated on the bottom, and the number of fruit flies that climbed 8cm or more from the starting point for 10 seconds was counted, and the experiment was repeated four times (n>10). For statistics, T-test was used, and the significance level (P) was set at 0.05, with P<0.05 considered to be significant.

[0085] As shown in Figure 4, the Parkinson's disease Drosophila model (DJ-1B EX54 ) showed a 25% decrease in climbing ability in the 4th week and a 24% decrease in climbing ability in the 5th week, while the Parkinson's model fruit fly (DJ-1B EX54 ) showed climbing ability similar to that of wild Drosophila until the 4th week, and at the 5th week, when the climbing ability of wild Drosophila was 69%, the Parkinson's model Drosophila (DJ-1B EX54 ) confirmed that the climbing ability was 51%, and these results confirmed that the medicinal bean bioconverted powder has the effect of improving behavioral disorders.

[0086] In addition, to confirm whether feeding the medicinal soybean bioconversion powder is effective in improving behavioral disorders in Drosophila under artificial oxidative stress, 5% sucrose containing 1% H2O2, 5% medicinal soybean bioconversion powder (enzyme-treated whole soy milk), and 5% sucrose containing 1% H2O2 were orally administered to a Drosophila model for 13 days, and the climbing assay and survival rate were confirmed. As shown in Figure 5, the behavioral disorders of Parkinson's model Drosophila (DJ-1B) under artificial oxidative stress were improved by administering 5% sucrose containing 1% H2O2 and 5% sucrose containing 5% H2O2. ex54) showed significantly lower climbing rates and survival rates, whereas DJ-1B, which was fed whole soy milk and biotransformed powder (enzyme-treated whole soy milk), showed significantly lower climbing rates and survival rates. ex54 Drosophila showed a higher climbing rate than the control group, and the group fed the medicinal bean biotransformation powder showed the highest survival rate.

[0087] As described above, certain parts of the present invention have been described in detail, but it is obvious to those skilled in the art that such specific descriptions are merely preferred embodiments and do not limit the scope of the present invention. That is, the substantial scope of the present invention is defined by the following claims and their equivalents.

Claims

1. A method for producing a medicinal bean biotransformation powder, comprising the step of treating a Bacillus polyfermenticus KMU01 (Accession Number: KCTC 11751BP) strain, a culture solution thereof, a fermented product thereof, or a mixture thereof at a concentration of 3-7% (v / v) based on total soybean milk at 35°C to 39°C for 3 hours to 5 hours, The medicinal bean biotransformation powder has increased branched chain amino acid (BCAA) contents of Val, Leu, and Ile, and aromatic amino acid contents of Phe and Tyr, compared to the whole soybean milk.

2. The method for producing medicinal bean biotransformation powder according to claim 1 , wherein the medicinal bean biotransformation powder exhibits antioxidant activity.

3. A pharmaceutical composition for preventing or treating behavioral disorders, comprising as an active ingredient whole soybean milk fermented with Bacillus polyfermenticus KMU01 (Accession Number: KCTC 11751BP), a culture solution thereof, a fermented product thereof, or a mixture thereof.

4. A health functional food composition for preventing or improving behavioral disorders, comprising as an active ingredient whole soy milk fermented with Bacillus polyfermenticus KMU01 (Accession Number: KCTC 11751BP) strain, its culture solution, its fermented product, or a mixture thereof.

Citation Information

Patent Citations

  • KR10-2008-0811615B1

  • Method for manufacturing whole soybean milk containing high content of active isoflavon

    KR1020110027247A

  • Novel salt-loving bacillus polyfermenticus strain for producing salt-tolerant gamma-glutamyl transpeptidase

    WO2020004809A1